{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:59:49Z","timestamp":1794473989592,"version":"4.9.1"},"reference-count":31,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,7,2]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>There is a strong negative association between comorbidities at diagnosis and overall survival. There is no negative effect of comorbidities on remission rates and progression to advanced phases in CML.<\/jats:p>","DOI":"10.1182\/blood-2015-01-617993","type":"journal-article","created":{"date-parts":[[2015,4,27]],"date-time":"2015-04-27T22:22:05Z","timestamp":1430173325000},"page":"42-49","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":177,"title":["Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV"],"prefix":"10.1182","volume":"126","author":[{"given":"Susanne","family":"Sau\u00dfele","sequence":"first","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Paloma","family":"Krau\u00df","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lauseker","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Proetel","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Kalmanti","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hanfstein","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Fabarius","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Kraemer","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Onkologie und H\u00e4matologie, Klinikum, Oldenburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang E.","family":"Berdel","sequence":"additional","affiliation":[{"name":"Medizinische Klinik A, Universit\u00e4tsklinikum, M\u00fcnster, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bentz","sequence":"additional","affiliation":[{"name":"Medizinische Klinik III, St\u00e4dtisches Klinikum, Karlsruhe, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Staib","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr H\u00e4matologie und Onkologie, St.-Antonius-Hospital, Eschweiler, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"de Wit","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr H\u00e4matologie, Onkologie und Palliativmedizin, Vivantes Klinikum Neuk\u00f6lln, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wernli","sequence":"additional","affiliation":[{"name":"Onkologie\/H\u00e4matologie und Transfusionsmedizin, Kantonsspital, Aarau, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Zettl","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr H\u00e4matologie und Medizinische Onkologie, Universit\u00e4tsmedizin, G\u00f6ttingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger F.","family":"Hebart","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Innere Medizin, Stauferklinikum, Mutlangen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hahn","sequence":"additional","affiliation":[{"name":"Ambulantes Onkologie Zentrum, Anspach, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Heymanns","sequence":"additional","affiliation":[{"name":"Praxisklinik f\u00fcr H\u00e4matologie und Onkologie, Koblenz, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Schmidt-Wolf","sequence":"additional","affiliation":[{"name":"Med. Klinik III, Onkologie, H\u00e4matologie und Rheumatologie, Universit\u00e4tsklinikum, Bonn, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr H\u00e4matologie und Stammzelltransplantation, Asklepios Klinik Hamburg St. Georg, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Eckart","sequence":"additional","affiliation":[{"name":"Internistische Schwerpunktpraxis, Erlangen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Gassmann","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr H\u00e4matologie und Internistische Onkologie, St. Marien-Krankenhaus, Siegen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bartholom\u00e4us","sequence":"additional","affiliation":[{"name":"Medizinische Klinik II, St. Bernward Krankenhaus, Hildesheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pezzutto","sequence":"additional","affiliation":[{"name":"Medizinische Klinik mit Schwerpunkt H\u00e4matologie und Onkologie, Campus Benjamin Franklin, Charit\u00e9-Universit\u00e4tsmedizin, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth Oppliger","family":"Leibundgut","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsspital Inselspital, Bern, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Heim","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr H\u00e4matologie, Universit\u00e4tsspital, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan W.","family":"Krause","sequence":"additional","affiliation":[{"name":"Medizinische Klinik 5, Universit\u00e4tsklinikum, Erlangen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Burchert","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr H\u00e4matologie, Onkologie und Immunologie, Universit\u00e4tsklinikum, Marburg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Karsten","family":"Hofmann","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Hasford","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"Abteilung H\u00e4matologie\/Internistische Onkologie, Universit\u00e4tsklinikum, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Pfirrmann","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2019111901382979900_B1","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia.","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111901382979900_B2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep Molecular Response (MR4.5) is reached by the majority of imatinib-treated patients, predicts survival, and is achieved faster by optimized high-dose imatinib - results from the randomized CML-Study IV.","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111901382979900_B3","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111901382979900_B4","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111901382979900_B5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111901382979900_B6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111901382979900_B7","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"2019111901382979900_B8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111901382979900_B9","doi-asserted-by":"crossref","first-page":"e76013","DOI":"10.1371\/journal.pone.0076013","article-title":"Comorbid diseases interact with breast cancer to affect mortality in the first year after diagnosis\u2014a Danish nationwide matched cohort study.","volume":"8","author":"Ording","year":"2013","journal-title":"PLoS ONE"},{"issue":"6","key":"2019111901382979900_B10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3324\/haematol.2013.096792","article-title":"Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials.","volume":"99","author":"Goede","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"2019111901382979900_B11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"11","key":"2019111901382979900_B12","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index.","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2019111901382979900_B13","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.leukres.2009.02.005","article-title":"Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes.","volume":"33","author":"Wang","year":"2009","journal-title":"Leuk Res"},{"issue":"10","key":"2019111901382979900_B14","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.3324\/haematol.2011.048991","article-title":"Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes.","volume":"96","author":"Breccia","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"2019111901382979900_B15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1586\/17474086.2013.837279","article-title":"Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.","volume":"6","author":"Gugliotta","year":"2013","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"2019111901382979900_B16","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3324\/haematol.2011.041251","article-title":"Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.","volume":"96","author":"Breccia","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2019111901382979900_B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.23330","article-title":"Long-term safety and efficacy of imatinib mesylate (Gleevec\u00ae) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study.","volume":"88","author":"Rousselot","year":"2013","journal-title":"Am J Hematol"},{"issue":"10","key":"2019111901382979900_B18","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111901382979900_B19","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"35","key":"2019111901382979900_B20","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111901382979900_B21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111901382979900_B22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2019111901382979900_B23","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia.","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"key":"2019111901382979900_B24","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV [published online ahead of print February 13, 2015].","author":"Kalmanti","journal-title":"Leukemia"},{"issue":"8","key":"2019111901382979900_B25","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q","article-title":"Evaluation of patients with advanced cancer using the Karnofsky performance status.","volume":"45","author":"Yates","year":"1980","journal-title":"Cancer"},{"issue":"9","key":"2019111901382979900_B26","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/leu.2011.116","article-title":"Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.","volume":"25","author":"Pfirrmann","year":"2011","journal-title":"Leukemia"},{"issue":"11","key":"2019111901382979900_B27","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models.","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"issue":"1","key":"2019111901382979900_B28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00277-013-1937-4","article-title":"Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.","volume":"93","author":"Kalmanti","year":"2014","journal-title":"Ann Hematol"},{"key":"2019111901382979900_B29","author":"Pfirrmann"},{"issue":"21","key":"2019111901382979900_B30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/blood.V124.21.153.153","article-title":"Survival and prognosis in patients with first-line imatinib treatment under particular consideration of death due to chronic myeloid leukemia.","volume":"124","author":"Pfirrmann","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111901382979900_B31","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/leu.2008.245","article-title":"Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph\/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany.","volume":"23","author":"Rohrbacher","year":"2009","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/1\/42\/1345249\/42.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/1\/42\/1345249\/42.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T01:38:47Z","timestamp":1574127527000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/126\/1\/42\/34347\/Impact-of-comorbidities-on-overall-survival-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-01-617993","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,2]]}}}